Oryzon Genomics SA (ORY) - Total Assets
Based on the latest financial reports, Oryzon Genomics SA (ORY) holds total assets worth €144.52 Million EUR (≈ $168.96 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Oryzon Genomics SA cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Oryzon Genomics SA - Total Assets Trend (2011–2025)
This chart illustrates how Oryzon Genomics SA's total assets have evolved over time, based on quarterly financial data. See ORY book value for net asset value and shareholders' equity analysis.
Oryzon Genomics SA - Asset Composition Analysis
Current Asset Composition (December 2025)
Oryzon Genomics SA's total assets of €144.52 Million consist of 21.2% current assets and 78.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 19.6% |
| Accounts Receivable | €2.24 Million | 1.6% |
| Inventory | €3.73K | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €109.22 Million | 75.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Oryzon Genomics SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ORY market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oryzon Genomics SA's current assets represent 21.2% of total assets in 2025, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 19.6% of total assets in 2025, up from 9.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 75.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 75.6% of total assets.
Oryzon Genomics SA Competitors by Total Assets
Key competitors of Oryzon Genomics SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.40 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896
|
China | CN¥3.22 Billion |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399
|
China | CN¥3.65 Billion |
Oryzon Genomics SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.95 | 0.75 | 5.51 |
| Quick Ratio | 1.94 | 0.74 | 5.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €14.90 Million | €-2.99 Million | €34.68 Million |
Oryzon Genomics SA - Advanced Valuation Insights
This section examines the relationship between Oryzon Genomics SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.79 |
| Latest Market Cap to Assets Ratio | 1.49 |
| Asset Growth Rate (YoY) | 32.9% |
| Total Assets | €144.52 Million |
| Market Capitalization | $214.95 Million USD |
Valuation Analysis
Above Book Valuation: The market values Oryzon Genomics SA's assets above their book value (1.49x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Oryzon Genomics SA's assets grew by 32.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Oryzon Genomics SA (2011–2025)
The table below shows the annual total assets of Oryzon Genomics SA from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €144.52 Million ≈ $168.96 Million |
+32.94% |
| 2024-12-31 | €108.72 Million ≈ $127.10 Million |
+1.70% |
| 2023-12-31 | €106.90 Million ≈ $124.98 Million |
+3.09% |
| 2022-12-31 | €103.70 Million ≈ $121.24 Million |
+8.72% |
| 2021-12-31 | €95.38 Million ≈ $111.51 Million |
+1.36% |
| 2020-12-31 | €94.11 Million ≈ $110.02 Million |
+17.49% |
| 2019-12-31 | €80.09 Million ≈ $93.64 Million |
+18.75% |
| 2018-12-31 | €67.45 Million ≈ $78.86 Million |
+10.50% |
| 2017-12-31 | €61.04 Million ≈ $71.37 Million |
+22.72% |
| 2016-12-31 | €49.74 Million ≈ $58.16 Million |
+22.13% |
| 2015-12-31 | €40.73 Million ≈ $47.62 Million |
+56.31% |
| 2014-12-31 | €26.06 Million ≈ $30.46 Million |
-9.40% |
| 2013-12-31 | €28.76 Million ≈ $33.63 Million |
-0.06% |
| 2012-12-31 | €28.78 Million ≈ $33.65 Million |
-1.48% |
| 2011-12-31 | €29.21 Million ≈ $34.15 Million |
-- |
About Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-… Read more